Blusense Diagnostics, a spin-out from the Technical University of Denmark (DTU),has launched its first product - a blood test to diagnose Dengue. The company expects to yield profit around 2022 and employ at least 70 people already next year.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.